Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (9960)	5/14/1999 11:32:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Bob, I think my post explained I am not talking about results. Total mortality is not a result. It is a fact. A result would be deaths per treatment and placebo group. I have urged XOMA to finally quit the crap and tell us what the mortality requirement was. That also is not a result and the FDA never said don't mention it. If the DSMB said don't mention it because it might impact the trial, now that the trial is over it can be disclosed. Bob, it's not just the science. I would hope everyone would realize how much dilution robs shareholders of the eventual payoff from the science you love, if there ever is one. Having to finance with floorless convertibles when the stock was already low hurts a company. Having to try to strike a deal when the other side knows you have a low cash position and they could buy your whole company for less than the amount a partnership would involve is not good. Shareholders get mistreated, not only at XOMA, because in large part they do nothing about it except sell their stock. A sizeable vote against management can be an important tool in getting them to do a better job.